Baby's hand holding its mother's finger

Newsroom

Latest News

News

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023

Sera Prognostics Inc., announced that it will report first quarter fiscal year 2023 financial results on Wednesday, May 10, 2023, after the close of the market.
News

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS

SALT LAKE CITY, March 22, 2023 — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and…
News

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023

Sera Prognostics, Inc., announced that it will report fourth quarter and full year 2022 financial results on Wednesday, March 22, 2023, after the close of the market.
News

SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES

Sera Prognostics Inc. announced that the company will present at the upcoming Cowen Health Care Conference March 6-8, 2023 in Boston and the Oppenheimer 33rd Annual Healthcare Conference held to be held virtually March 13-15, 2023.
News

Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL

PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay
News

FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS

Sera Prognostics and Fors Marsh are collaborating to provide Sera’s PreTRM® Test to employees at Fors Marsh as part of their maternity benefits, effective January 1, 2023.
News

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS

Sera Prognostics Inc. announced the publication of results from a clinical utility and cost-effectiveness modeling study, ACCORDANT (Analyses aCross Congruent studies ReDucing Adverse pregNancy ouTcomes).
News

SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today…
News

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9

Sera Prognostics announced that it will report third quarter fiscal year 2022 financial results on Wednesday, November 9, 2022, after the close of the market.
News

SONRAVA HEALTH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH CEREBRAE AND SERA PROGNOSTICS

Sera Prognostics Inc., focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, Sonrava Health, a national family of health and wellness companies, and Cerebrae, an innovator in pricing and measuring the financial value of care, are collaborating to provide Sera’s PreTRM® Test to members of Sonrava Health’s employer-sponsored health insurance program.

Stay in Touch